AI startup Nucleai has immuno-oncology treatment failures in...

Israeli company Nucleai is putting artificial intelligence to work to discover why so many cancer patients don’t respond to immunotherapies, with the help of Swiss drugmaker De

Novartis closes on EU approval for breast cancer drug Piqray

Novartis has moved nearer to claiming approval for its PI3K inhibitor Piqray for breast cancer in the EU, one of a crop of new drugs that the company thinks have blockbuster sa

NICE and Roche reach funding deal for Tecentriq in triple ne...

NICE has recommended regular NHS funding for Roche’s immunotherapy Tecentriq (atezolizumab) in tough-to-treat advanced triple negative breast cancer in final draft guidance, after a previou

Seattle Genetics snags early approval for advanced breast ca...

The FDA has approved Seattle Genetics' breast cancer drug Tukysa (tucatinib) four months early, including in certain patients whose disease has spread to the brain.

FDA sets August action date for Seattle’s oral HER2 drug tuc...